AVTR logo

Avantor Inc. (AVTR)

$15.32

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on AVTR

Market cap

$10.38B

EPS

0.5

P/E ratio

--

Price to sales

1.62

Dividend yield

--

Beta

0.948971

Price on AVTR

Previous close

$15.54

Today's open

$15.46

Day's range

$15.27 - $15.62

52 week range

$7.27 - $17.45

Profile about AVTR

CEO

Emmanuel Ligner

Employees

13500

Headquarters

Radnor, PA

Exchange

New York Stock Exchange

Shares outstanding

677615769

Issue type

Common Stock

AVTR industries and sectors

Healthcare

Biotechnology & Life Sciences

News on AVTR

Avantor: 3 Key Takeaways for Long-Term Investors

Avantor reported 5.2% organic revenue growth in the third quarter. VWR distribution organic sales increased 5.8% on higher customer volume.

news source

The Motley Fool • Nov 12, 2026

news preview

Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?

Here is how Avantor, Inc. (AVTR) and Novartis (NVS) have performed compared to their sector so far this year.

news source

Zacks Investment Research • Oct 30, 2026

news preview

Avantor, Inc. (AVTR) is a Great Momentum Stock: Should You Buy?

Does Avantor, Inc. (AVTR) have what it takes to be a top stock pick for momentum investors? Let's find out.

news source

Zacks Investment Research • Oct 30, 2026

news preview

Avantor (AVTR) Upgraded to Buy: What Does It Mean for the Stock?

Avantor (AVTR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

news source

Zacks Investment Research • Oct 30, 2026

news preview

What Avantor (AVTR) Said on Its Q3 Earnings Call

Avantor NYSE: AVTR reported a return to organic revenue growth in the third quarter of 2026, led by accelerating performance in its VWR Distribution & Services segment and a return to growth in its Bioscience & Medtech Products business.

news source

MarketBeat • Oct 28, 2026

news preview

Avantor, Inc. (AVTR) Q3 2026 Earnings Call Transcript

Avantor, Inc. ( AVTR ) Q3 2026 Earnings Call October 28, 2026 8:00 AM EDT Company Participants Chris Fidyk - Vice President of Investor Relations Emmanuel Ligner - President, CEO & Director Todd Garner - Executive VP & CFO Steven Eck - Senior VP, Corporate Controller & Chief Accounting Officer Conference Call Participants Casey Woodring - JPMorgan Chase & Co, Research Division Luke Sergott - Barclays Bank PLC, Research Division Douglas Schenkel Tycho Peterson - Jefferies LLC, Research Division Eve Burstein - Bernstein Institutional Services LLC, Research Division Justin Bowers - Deutsche Bank AG, Research Division Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good morning. My name is Krista, and I will be your conference operator today.

news source

Seeking Alpha • Oct 28, 2026

news preview

Avantor® Reports Third Quarter 2026 Results

Net sales of $1,698.3 million; increase of 4.6%; organic increase of 5.2% Diluted GAAP EPS of $0.30; adjusted EPS of $0.22 Raised FY 2026 organic revenue growth, adjusted EPS and free cash flow guidance RADNOR, Pa., Oct. 28, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, reports results that exceeded management's expectations for revenue and adjusted EPS for the third fiscal quarter of 2026.

news source

PRNewsWire • Oct 28, 2026

news preview

Avantor, Inc. (AVTR) Surpasses Q3 Earnings and Revenue Estimates

Avantor, Inc. (AVTR) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.22 per share a year ago.

news source

Zacks Investment Research • Oct 28, 2026

news preview

Avantor appoints new Chief Information Officer

RADNOR, Pa., Oct. 26, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, welcomes Mikey Santiago as its new Chief Information Officer.

news source

PRNewsWire • Oct 26, 2026

news preview

Longleaf Partners Fund Q3 2026 Portfolio Review

The market is regaining confidence in Avantor's ability to grow organically and in Emmanuel Ligner's turnaround plan. Biopharma company Regeneron reported a solid set of results, with key drug Dupixent continuing to outpace our and the market's growth expectations. Building products company Fortune Brands Innovations saw its stock price decline in Q3, retracing Q2's positive move related to excitement over Jesse Singh's appointment as CEO.

news source

Seeking Alpha • Oct 14, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Avantor Inc.

Open an M1 investment account to buy and sell Avantor Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in AVTR on M1